JP Morgan Initiates Coverage On Definium Therapeutics with Overweight Rating, Announces Price Target of $84

JP Morgan has initiated coverage on Definium Therapeutics (NASDAQ: DFTX) with an Overweight rating, setting a price target of $84 for the stock. This move indicates a positive outlook for the company's future performance in the market.